Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disulfiram and Its Derivatives: An Immortal Phoenix of Drug Repurposing.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

In Vitro and In Vivo Preventive Effects of Thymoquinone against Breast Cancer: Role of DNMT1.

Molecules (Basel, Switzerland)·2024
Same author

Design, synthesis, and anti-hepatocellular carcinoma of thiopyrimidine/chalcone hybrids as dual STAT3/STAT5 inhibitors.

RSC medicinal chemistry·2023
Same author

<i>Nigella sativa</i>-Manganese Ferrite-Reduced Graphene Oxide-Based Nanomaterial: A Novel Adsorbent for Water Treatment.

Molecules (Basel, Switzerland)·2023
Same author

Exploring the Antimicrobial Activity of Sodium Titanate Nanotube Biomaterials in Combating Bone Infections: An In Vitro and In Vivo Study.

Antibiotics (Basel, Switzerland)·2023
Same author

Antidiabetic and Anticancer Potentials of <i>Mangifera indica</i> L. from Different Geographical Origins.

Pharmaceuticals (Basel, Switzerland)·2023

Related Experiment Video

Updated: Jun 9, 2025

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

5.2K

Geldanamycins: Potent Hsp90 Inhibitors with Significant Potential in Cancer Therapy.

Omeima Abdullah1, Ziad Omran2

  • 1College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia.

International Journal of Molecular Sciences
|October 26, 2024
PubMed
Summary

Geldanamycin, a heat shock protein inhibitor, shows promise but has toxicity issues. Strategies like drug delivery systems and combinations are being explored to improve its clinical efficacy and reduce side effects.

Keywords:
Hsp90PROTACansamycincancergeldanamycinmutasynthesis

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.7K
Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
06:51

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Published on: July 21, 2021

2.7K

Related Experiment Videos

Last Updated: Jun 9, 2025

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

5.2K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.7K
Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
06:51

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay

Published on: July 21, 2021

2.7K

Area of Science:

  • Pharmacology
  • Oncology
  • Molecular Biology

Background:

  • Geldanamycin, an ansamycin macrolide from *Streptomyces hygroscopicus*, inhibits heat shock protein 90 (Hsp90).
  • It exhibits potent antiproliferative activity but suffers from significant hepatotoxicity and poor pharmacokinetics.
  • Despite clinical trials, no geldanamycin analogs have achieved FDA approval.

Purpose of the Study:

  • To review the mechanism of action of geldanamycin.
  • To discuss its pharmacokinetic properties and toxicity.
  • To explore strategies for enhancing its clinical efficacy and safety.

Main Methods:

  • Literature review of geldanamycin and its analogs.
  • Analysis of preclinical and clinical data.
  • Discussion of drug delivery systems, prodrug approaches, and combination therapies.

Main Results:

  • Geldanamycin's Hsp90 inhibition underlies its antiproliferative effects.
  • Hepatotoxicity and unfavorable pharmacokinetics limit its clinical use.
  • Several geldanamycin derivatives have entered clinical trials, with ongoing research into toxicity mitigation.

Conclusions:

  • Strategies such as nanocarrier delivery and prodrugs are crucial for overcoming geldanamycin's toxicity.
  • Combination therapies may enhance efficacy and circumvent resistance mechanisms.
  • Further development is needed to optimize geldanamycin analogs for clinical application.